Short-term Efficacy Of Sacubitril/valsartan In Patients With Two Different Etiologies Of HFrEF

Objective: To evaluate the short-term clinical efficacy of sacubitril/valsartan in patients with heart failure with reduced ejection fraction caused by two different etiologies.Methods: From December 2019 to July 2020,HFr EF patients meeting the inclusion criteria of this experiment were randomly selected as the research subjects in the patients of Loudi Central Hospital.According to the etiology,the patients were divided into coronary heart disease group(n=40)and dilated cardiomyopathy group(n=40).all enrolled patients received sacubitril/valsartan therapy.The target dose/maximum tolerated dose was titrated gradually according to the patient’s individual tolerance.In addition,patients in each group were all given conventional anti-heart failure treatment regiments,including lifestyle intervention,health education,and removal of heart failure causes.Routine anti-heart failure drug therapy was given individually and pertinently.NYHA classification,NT-pro BNP,LVESD,LVEDD,LVEF were compared between the two groups before and after treatment and contrast the rate of readmission and incidence of MACE after 6 months’ treatment.Results:1.After 6 months of treatment with sacubitril/valsartan,There was a difference in the overall effective rate between the two groups.In addition,the decrease level of NT-pro BNP in the coronary heart disease group were more significant than the dilated cardiomyopathy group,the difference was statistically significant(P<0.05).2.During the 6 months follow-up,The readmission rate and MACE rate of two groups were different,the coronary heart disease group were lower than the dilated cardiomyopathy group,the difference was statistically significant(P<0.05).Conclusion:Compared with dilated cardiomyopathy patients,sacubitril/valsartan is more effective in patients of heart failure with reduced ejection fraction caused by ischemic cardiomyopathy to some extent.